2014
Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study)
Kelly CR, Weisz G, Maehara A, Mintz GS, Mehran R, Lansky AJ, Parise H, de Bruyne B, Serruys PW, Stone GW. Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study). The American Journal Of Cardiology 2014, 114: 376-383. PMID: 24931291, DOI: 10.1016/j.amjcard.2014.04.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCoronary AngiographyCoronary Artery DiseaseC-Reactive ProteinDisease ProgressionFemaleGlobal HealthHumansIncidenceInflammationMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSurvival RateTime FactorsConceptsMajor adverse cardiac eventsC-reactive protein levelsNonculprit lesionsElevated CRP levelsCRP levelsVulnerable coronary plaquesIntravascular ultrasoundCoronary plaquesPost-acute coronary syndrome patientsSubsequent major adverse cardiac eventsGray-scale intravascular ultrasoundCoronary Tree (PROSPECT) studyUntreated nonculprit lesionsAdverse cardiac eventsAdverse coronary eventsAcute coronary syndromeCoronary syndrome patientsPercutaneous coronary interventionRadiofrequency intravascular ultrasoundPredictors of eventsProtein levelsMinimal luminal areaHigh rateCoronary eventsCoronary syndrome
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban